Rana Anjum

Tumor-promoting phorbol esters and activated Ras inactivate the tuberous sclerosis tumor suppressor complex via p90 ribosomal S6 kinase

Philippe P. Roux, Bryan A. Ballif, Rana Anjum et al. · Proceedings of the National Academy of Sciences · 2004 · 741 citations · Full text

Life Sciences, Cell Biology, Oncology +17

Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma Kinase

Wei‐Sheng Huang, Shuangying Liu, Dong Zou et al. · Journal of Medicinal Chemistry · 2016 · 404 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +13

The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models

Sen Zhang, Rana Anjum, Rachel M. Squillace et al. · Clinical Cancer Research · 2016 · 326 citations · Full text

Medicine, Oncology, Pharmacology +15

Inactivation of the Tuberous Sclerosis Complex-1 and -2 Gene Products Occurs by Phosphoinositide 3-Kinase/Akt-dependent and -independent Phosphorylation of Tuberin

Andrew R. Tee, Rana Anjum, John Blenis · Journal of Biological Chemistry · 2003 · 214 citations · Full text

Life Sciences, Cell Biology, Molecular Genetics +16

Ponatinib Inhibits Polyclonal Drug-Resistant KIT Oncoproteins and Shows Therapeutic Potential in Heavily Pretreated Gastrointestinal Stromal Tumor (GIST) Patients

Andrew P. Garner, Joseph M. Gozgit, Rana Anjum et al. · Clinical Cancer Research · 2014 · 160 citations

Medicine, Oncology, Pharmacology +15